Trial Profile
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-006
- Sponsors Merck Sharp & Dohme Corp.
- 22 Jun 2023 Results assessing efficacy of 7-year follow-up published in the Journal of Clinical Oncology.
- 25 Oct 2021 Results of post hoc analysis of KEYNOTE-006 evaluating outcomes with ipilimumab or BRAFi , MEKi as first subsequent systemic therapy after pembrolizumab and includes patients who completed or discontinued pembrolizumab published in the Annals of Oncology
- 24 Sep 2021 Results of post-hoc analysis of two studies (KEYNOTE-001 and KEYNOTE-006) assessing long-term outcomes for patients with early SD, partial response (PR) or complete response (CR) with pembrolizumab, published in the European Journal of Cancer.